Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) EBT (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed EBT for 7 consecutive years, with -$21.7 million as the latest value for Q4 2025.

  • Quarterly EBT rose 56.27% to -$21.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$147.5 million through Dec 2025, up 29.86% year-over-year, with the annual reading at -$147.5 million for FY2025, 29.86% up from the prior year.
  • EBT for Q4 2025 was -$21.7 million at Pliant Therapeutics, up from -$26.3 million in the prior quarter.
  • The five-year high for EBT was -$21.7 million in Q4 2025, with the low at -$57.8 million in Q3 2024.
  • Average EBT over 5 years is -$37.0 million, with a median of -$36.3 million recorded in 2022.
  • The sharpest move saw EBT crashed 307.24% in 2021, then surged 56.27% in 2025.
  • Over 5 years, EBT stood at -$24.5 million in 2021, then plummeted by 42.92% to -$35.1 million in 2022, then decreased by 17.25% to -$41.1 million in 2023, then dropped by 20.98% to -$49.7 million in 2024, then soared by 56.27% to -$21.7 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$21.7 million, -$26.3 million, and -$43.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.